Biotek-snakken — Juli 2025
-
Godmorgen
-
JNJ siger i deres Q2 CC: And then finally, in prostate cancer. We have great momentum across our pipeline, most recently reporting, for example, an exciting bispecific T-cell engager, pasritamig, that we think has enormous potential to really transform the practice of medicine in prostate.
-
I'm super excited about our icotrokinra, the oral targeted peptide inhibitor of the IL-23 receptor, which did achieve a compelling proof of concept in ulcerative colitis. We'll be showing those data later this year at a medical meeting. We have begun gearing up now to do a broad Phase III campaign in both UC and Crohn's disease based on those compelling data
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind